Continue durvalumab after finishing a prior cancer study
Treatments studied
Part of Cancer clinical trials.
This study lets people who already finished (or can no longer continue) an earlier AstraZeneca cancer treatment study keep receiving durvalumab. It tests whether continuing the same kind of treatment on a regular schedule can help keep your cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign a written consent form and agree to join the study.
- You are currently doing well enough on your earlier AstraZeneca cancer study to get ongoing benefit, or you finished that study because of timing limits.
- At study start, you must be able to receive durvalumab as 1500 mg once every 3 months (every 4 weeks, for 4-week intervals).
- You should NOT have had serious (Grade 3 or higher) side effects that were still not resolved when your earlier study ended.
- You should NOT be taking any study-prohibited medicines or joining other medical research that could interfere with this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether durvalumab (an immunotherapy) can still help treat advanced cancer after you had to stop an earlier immune checkpoint medicine because of immune-related side effects. If you’re already on a durvalumab-based study, Substudy B also looks at continuing durvalumab (with or without tremelimumab) when it’s safe for you.
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
This trial is for people with limited-stage small cell lung cancer who have already finished chemotherapy and radiation, and then started taking Durvalumab (Imfinzi) as a maintenance therapy. The goal is to see if continuing Durvalumab helps keep the cancer from coming back.
This trial tests adding durvalumab (an immune therapy) to a radiation treatment plan for people with non-small cell lung cancer (NSCLC) who can’t safely have chemotherapy at the same time or surgery first. It aims to improve cancer control after radiation by helping the immune system recognize and fight the tumor.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.